1
|
Kolk M, Frodi DM, Langford J, Meskers CJ, Andersen TO, Jacobsen PK, Risum N, Tan HL, Svendsen JH, Knops RE, Diederichsen SZ, Tjong F. Behavioural digital biomarkers enable real-time monitoring of patient-reported outcomes: a substudy of the multicenter, prospective observational SafeHeart study. Eur Heart J Qual Care Clin Outcomes 2023:qcad069. [PMID: 38059857 DOI: 10.1093/ehjqcco/qcad069] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/08/2023]
Abstract
INTRODUCTION Patient-reported outcome measures (PROMs) serve multiple purposes, including shared decision-making and patient communication, treatment monitoring and health-technology assessment. Patient monitoring using PROMs is constrained by recall and non-response bias, respondent burden and missing data. We evaluated the potential of behavioural digital biomarkers obtained from a wearable accelerometer to achieve personalised predictions of PROMs. METHODS Data from the multicenter, prospective SafeHeart study conducted at Amsterdam University Medical Center in the Netherlands and Copenhagen University Hospital, Rigshospitalet in Copenhagen, Denmark, was used. The study enrolled patients with an implantable cardioverter defibrillator (ICD) between May 2021 and September 2022 who then wore wearable devices with raw acceleration output to capture digital biomarkers reflecting physical behaviour. To collect PROMs, patients received the KCCQ and EQ5D-5 L questionnaire at two instances; baseline and after 6 months. Multivariable Tobit regression models were used to explore associations between digital biomarkers and PROMs, specifically whether digital biomarkers could enable PROM prediction. RESULTS The study population consisted of 303 patients (mean age 62.9 ± 10.9 years, 81.2% male). Digital biomarkers showed significant correlations to patient-reported physical and social limitations, severity and frequency of symptoms and quality of life. Prospective validation of the Tobit models indicated moderate correlations between the observed and predicted scores for KCCQ (concordance correlation coefficient (CCC) = 0.49, mean difference: 1.07 points) and EQ5D-5 L (CCC = 0.38, mean difference 0.02 points). CONCLUSION Wearable digital biomarkers correlate with PROMs, and may be leveraged for real-time prediction. These findings hold promise for monitoring of PROMs through wearable accelerometers.
Collapse
Affiliation(s)
- Mzh Kolk
- Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - D M Frodi
- Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark
| | - J Langford
- Activinsights Ltd, Kimbolton, UK
- College of Life and Environmental Sciences, University of Exeter, Exeter, UK
| | - C J Meskers
- Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - T O Andersen
- Vital Beats, Copenhagen, Denmark
- Department of Computer Science, University of Copenhagen, Copenhagen, Denmark
| | - P K Jacobsen
- Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark
| | - N Risum
- Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark
| | - H L Tan
- Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
- Netherlands Heart Institute, Utrecht, The Netherlands
| | - J H Svendsen
- Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark
- Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
| | - R E Knops
- Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| | - S Z Diederichsen
- Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark
| | - Fvy Tjong
- Department of Cardiology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
2
|
Westergaard L, Joens C, Kroell J, Kristensen SL, Johannessen A, Sandgaard N, Gang UJO, Hansen PS, Riahi S, Kristiansen SB, Fosboel EL, Pehrson S, Chen X, Jacobsen PK, Weeke PE. Heart failure hospitalizations and diuretic use before and after first-time pulmonary vein isolation ablation for atrial fibrillation among patients with heart failure. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.593] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Background
Small randomized clinical trials have found that patients with heart failure (HF) and atrial fibrillation (AF) randomized to an ablation strategy for AF experienced improved cardiovascular outcomes. We examined the relation in routine clinical practice.
Purpose
We aimed to assess if first-time pulmonary vein isolation ablation (PVI) for AF among patients with HF was associated with decrease in HF hospital admissions rates and furosemide dosage in the year after PVI compared with the year before.
Methods
We identified patients with HF and available left ventricular ejection fraction (LVEF) treated with a first-time PVI using the Danish Ablation Registry, and alive at 1-year follow-up. Patient comorbidities and concomitant pharmacotherapy (including furosemide dosage and HF hospital admissions) were identified utilizing Danish nationwide registries. For inclusion, patients were required to have been diagnosed with HF in an in- or outpatient setting <10 years of first-time PVI or have a LVEF at the time of PVI ≤45%. Patients were grouped according to LVEF at time of PVI: ≤35%, 36–45%, and >45%. For comparison of HF hospital admission and furosemide usage before and after PVI, McNemars test were used. Wilcox signed-rank test were used to test difference in furosemide dosage before and after PVI.
Results
We identified 668/3450 patients with HF treated with first-time PVI for AF between 2010–2017 (median age 62 years [Q1,Q3=56,69 years], 81% male, and median LVEF 45% [Q1,Q3=40,60%]). Of these, 13 patients (2%) died during one-year follow-up. Overall, 36% of patients with HF had one or more HF hospital admissions the year before PVI compared with 7% in the year after PVI (p<0.0001) (Figure 1). Patients with LVEF ≤35% had the highest proportion of HF hospital admissions the year before PVI (53%) and was reduced more than 4-fold (13%) in the year after first-time PVI, with consistent findings in all LVEF groups (Figure 1). At the time of PVI, 36% of patients with HF were treated with furosemide compared with 30% in the year after PVI (p<0.0001) (Figure 2). Moreover, we identified significant reductions in furosemide dose in the year after PVI compared with the year before (median dose 60 mg [Q1,Q3=30,80 mg] and 20 mg [Q1,Q3=0,60 mg], respectively, p=0.001). Here, reductions in furosemide requirements were consistent across LVEF subgroups.
Conclusion
Patients with HF treated with a first-time PVI strategy for AF had a 5-fold decrease in HF hospital admissions in the following year compared with the year before PVI. Among patients treated with furosemide at time of PVI, significant reductions in dose one year after PVI was identified but also significant reductions in proportion of patients requiring any furosemide at all.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- L Westergaard
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, The Heart Centre , Copenhagen , Denmark
| | - C Joens
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, The Heart Centre , Copenhagen , Denmark
| | - J Kroell
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, The Heart Centre , Copenhagen , Denmark
| | - S L Kristensen
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, The Heart Centre , Copenhagen , Denmark
| | - A Johannessen
- Gentofte University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - N Sandgaard
- Odense University Hospital, Department of Cardiology , Odense , Denmark
| | - U J O Gang
- Zealand University Hospital, Department of Cardiology , Roskilde , Denmark
| | | | - S Riahi
- Aalborg University Hospital, Department of Cardiology , Aalborg , Denmark
| | - S B Kristiansen
- Aarhus University Hospital, Department of Cardiology , Aarhus , Denmark
| | - E L Fosboel
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, The Heart Centre , Copenhagen , Denmark
| | - S Pehrson
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, The Heart Centre , Copenhagen , Denmark
| | - X Chen
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, The Heart Centre , Copenhagen , Denmark
| | - P K Jacobsen
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, The Heart Centre , Copenhagen , Denmark
| | - P E Weeke
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, The Heart Centre , Copenhagen , Denmark
| |
Collapse
|
3
|
Thomsen AF, Winkel BG, Jons C, Bertelsen L, Bhardwaj P, Stampe NK, Kober L, Engstrom T, Vejlstrup NG, Jacobsen PK. Myocardial scarring and recurrence of ventricular arrhythmia in patients surviving a ventricular fibrillation out of hospital cardiac arrest. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Prediction of ventricular arrhythmia recurrence in survivors of ventricular fibrillation out of hospital cardiac arrest (VF-OHCA) is important, but currently difficult. Risk of recurrence may be related to presence of myocardial scarring and dedicated late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) software allows for characterization of left ventricular scarring, including differentiation between core, border zone (BZ) and BZ channels that represent potential electrical circuits of slow conductivity responsible for ventricular arrhythmic events.
Purpose
Our study aims to characterize myocardial scarring as defined by LGE-CMR in survivors of a VF-OCHA and investigate its potential role for the risk of new ventricular arrhythmia.
Methods
Between 2018 and 2021, a total of 130 VF-OHCA patients had CMR, of which we included 28 patients with LGE-CMR before ICD implantation for secondary prevention. A total of 15 (54%) patients had signs of acute or chronic ischemic heart disease (IHD); and 13 (46%) patients had arrhythmogenic cardiomyopathy (ACM). Scar tissue including core, BZ and BZ channels were automatically detected by specialized investigational software. To differentiate BZ from healthy tissue and BZ from core, thresholds of 40% ± 5% and 60% ± 5% of the maximum signal intensity were applied. A BZ channel in the LGE-CMR reconstruction was defined as a continuous corridor of BZ between 2 core areas or between a core area and a valve annulus (Figure 1A+B).
Results
The median age was 56 years; 86% were men and the median left ventricular ejection fraction was 50±11%. A total of 16 (57%) patients had an inferior scar on LGE-CMR, and 8 (29%) patients with IHD were incompletely revascularized. After a median follow-up of 98 days, 9 (32%) patients (6/9 with IHD, including 5/6 incompletely revascularized; 3/9 with ACM) had recurrence of ventricular arrhythmia (6/9 monomorphic ventricular tachycardia (VT)). A significantly higher number of patients with BZ channels had recurrence of ventricular arrhythmia compared with patients without BZ channels (7/11 vs. 2/17; P=0.01) (Figure 2). The number of BZ channels (3±1 vs. 2±1; P=0.13); scar mass (21±8g vs. 14±11g; P=0.21); core mass (7±4g vs. 4±5g; P=0.14); and BZ mass (11±5g vs. 9±7g; P=0.42) were insignificantly higher in patients with recurrent ventricular arrhythmia compared with patients without.
Conclusion
Borderzone channels analyzed by LGE-CMR were associated with subsequent recurrence of ventricular arrhythmia in patients with out of hospital cardiac arrest caused by ventricular fibrillation.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A F Thomsen
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | - B G Winkel
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | - C Jons
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | - L Bertelsen
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | - P Bhardwaj
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | - N K Stampe
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | - L Kober
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | - T Engstrom
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | - N G Vejlstrup
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| | - P K Jacobsen
- Rigshospitalet - Copenhagen University Hospital , Copenhagen , Denmark
| |
Collapse
|
4
|
Alhakak A, Philbert BT, Risum N, Mogensen UM, Jons C, Jacobsen PK, Haarbo J, Johansen JB, Nielsen JC, Riahi S, Torp-Pedersen C, Fosbol EL, Kober L, Vinther M, Weeke PE. Risk of lead explantation after first-time implantation of cardiac implantable electronic device as a function of comorbidity: a nationwide study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.749] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The benefit of cardiac implantable electronic devices (CIEDs) is challenged by the risk of procedure-related complications and lead explantation. Whether patient comorbidity burden is associated with risk of lead explantation <6 months of implantation is unknown.
Purpose
We assessed the risk of lead explantation and its association with comorbidity burden within 6 months after first-time CIED implantation.
Methods
The study population comprised patients ≥18 years old with first-time CIED implantation (i.e., pacemaker [PM], implantable cardioverter defibrillator [ICD], and cardiac resynchronisation therapy with defibrillator [CRT-D] or without [CRT-P]) using Danish nationwide registries including the Danish Pacemaker and ICD registry (1 January 2000 to 30 June 2018). Patients were followed from their first-time CIED implantation and 6 months forward. Patient comorbidity burden was categorised in four groups according to the Charlson Comorbidity Index (CCI) score: 0 (none), 1–2 (mild), 3–4 (moderate), and ≥5 (severe). Multivariable cause-specific Cox regression was performed to assess risk of lead explantation according to comorbidity burden, with death as competing risk. Comorbidity burden was adjusted for sex, age, type of CIED, and body mass index categories.
Results
We identified 73,491 patients with first-time CIED implantation including 55,733 (75.8%) with PM, 11,351 (15.5%) with ICD, 2,989 (4.1%) with CRT-P, and 3,418 (4.7%) with CRT-D. In total, 1,049 (1.4%) patients underwent lead explantation. The median age of the study population was 75.1 years [25th-75th percentile 66.2–82.5 years], and 62.1% were male. Patients undergoing lead explantation had higher median CCI score, compared with those not undergoing lead explantation (2 [1–3] and 1 [0–3], respectively). The median age and distribution of sex were similar in both groups. In the multivariable Cox regression model (Figure 1), an increase in patient comorbidity burden was associated with higher hazard ratio [HR] of lead explantation, compared with CCI score 0 (CCI score 1–2: HR=1.38 [95% confidence interval [CI]: 1.12–1.69], CCI score 3–4: HR=1.61 [95% CI: 1.28–2.03], and CCI score ≥5: HR=1.60 [95% CI: 1.25–2.05]).
Conclusion
Risk of lead explantation within 6 months after first-time implantation of cardiac implantable electronic device was 1.4% and associated with higher comorbidity burden.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): Independent Research Fund Denmark
Collapse
Affiliation(s)
- A Alhakak
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - B T Philbert
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - N Risum
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - U M Mogensen
- Zealand University Hospital, Department of Cardiology , Roskilde , Denmark
| | - C Jons
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - P K Jacobsen
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - J Haarbo
- Gentofte Hospital - Copenhagen University Hospital, Department of Cardiology , Hellerup , Denmark
| | - J B Johansen
- Odense University Hospital, Department of Cardiology , Odense , Denmark
| | - J C Nielsen
- Aarhus University Hospital, Department of Cardiology , Aarhus , Denmark
| | - S Riahi
- Aalborg University Hospital, Department of Cardiology , Aalborg , Denmark
| | - C Torp-Pedersen
- Nordsjaellands Hospital, Department of Clinical Research and Cardiology , Hilleroed , Denmark
| | - E L Fosbol
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - L Kober
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - M Vinther
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - P E Weeke
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| |
Collapse
|
5
|
McEvoy Kjaer E, Malta Westergaard L, Thornvig Philbert B, Vinther M, Haider Butt J, Kroell J, Joens C, Karl Jacobsen P, Brock Johansen J, Cosedis Nielsen J, Riahi S, Haarbo J, Fosboel E, Koeber L, Ejvin Kure Weeke P. History of betablocker treatment breaks and risk of ventricular tachyarrhythmias among patients with heart failure and implantable cardioverter defibrillator: a nationwide cohort study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.726] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Beta-blockers have in randomized clinical trials been shown to reduce the risk of life-threatening arrhythmias and sudden cardiac death (SCD) in patients with heart failure (HF), and treatment is a class 1A recommendation in current guidelines. Thus, beta-blocker treatment breaks (i.e. planned break, beta-blocker related side-effects, or poor adherence) may increase risk of life-threatening arrhythmias and SCD. Whether patients with HF and a history of beta-blocker treatment breaks before implantable cardioverter defibrillator (ICD) is associated with increased risk of device related therapy and mortality is largely unknown.
Aims
In patients with HF and an ICD alone or combined with cardiac resynchronization therapy (CRT-D), we examined the association between a history of a beta-blocker treatment breaks prior to device implantation and the risk of appropriate and inappropriate device related therapy (i.e., anti-tachycardia pacing [ATP] or DC shock [DC]), and all-cause mortality.
Methods
Using the Danish Pacemaker and ICD Registry, we identified all patients with HF receiving a first-time ICD (2000–2018). Beta-blocker treatment breaks >60 consecutive days up to 3 years prior to device implantation were identified using the National Prescription Registry. Patients were able to switch between beta-blockers and were required to be in treatment at the time of implantation. We used multivariable Cox regressions to compare the 1-year risks of device-related therapy and all-cause mortality between patients with and without a history of a beta-blocker treatment break.
Results
We identified 9,239 patients with HF and an ICD (82.6% male; median age 67 years). A total of 82.5% had ischemic heart disease, 33.9% atrial fibrillation, and 33.1% of ICDs were secondary prophylaxis. During one-year follow-up, 5.7% of all patients died and appropriate DC and appropriate ATP was identified for 3.9% and 6.7% of patients, respectively. Overall, 14.6% of all HF patients had one or more beta-blocker treatment break >60 days. Compared with HF patients with no history of treatment breaks, a history of treatment breaks >60 days were associated with increased risk of appropriate DC (hazard ratio (HR)=1.33; 95% confidence interval [CI], 1.02–1.73) and appropriate ATP (HR 1.30; CI, 1.06–1.59), but also inappropriate DC and ATP therapy (Figure 1). There was no difference between groups with respect to all-cause mortality (HR=0.96; CI: 0.76–1.22). Treatment breaks of >30 or >90 days were also evaluated and yielded similar results as the main analysis.
Conclusion
Patients with heart failure who had a history of treatment breaks with beta-blockers prior to ICD implantation was associated with a higher 1-year risk of appropriate and inappropriate shocks and anti-tachycardia pacing, but not all-cause mortality.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- E McEvoy Kjaer
- Rigshospitalet - Copenhagen University Hospital, Cardiology , Copenhagen , Denmark
| | - L Malta Westergaard
- Rigshospitalet - Copenhagen University Hospital, Cardiology , Copenhagen , Denmark
| | - B Thornvig Philbert
- Rigshospitalet - Copenhagen University Hospital, Cardiology , Copenhagen , Denmark
| | - M Vinther
- Rigshospitalet - Copenhagen University Hospital, Cardiology , Copenhagen , Denmark
| | - J Haider Butt
- Rigshospitalet - Copenhagen University Hospital, Cardiology , Copenhagen , Denmark
| | - J Kroell
- Rigshospitalet - Copenhagen University Hospital, Cardiology , Copenhagen , Denmark
| | - C Joens
- Rigshospitalet - Copenhagen University Hospital, Cardiology , Copenhagen , Denmark
| | - P Karl Jacobsen
- Rigshospitalet - Copenhagen University Hospital, Cardiology , Copenhagen , Denmark
| | | | | | - S Riahi
- Aalborg University Hospital, Cardiology , Aalborg , Denmark
| | - J Haarbo
- Gentofte University Hospital, Cardiology , Gentofte , Denmark
| | - E Fosboel
- Rigshospitalet - Copenhagen University Hospital, Cardiology , Copenhagen , Denmark
| | - L Koeber
- Rigshospitalet - Copenhagen University Hospital, Cardiology , Copenhagen , Denmark
| | - P Ejvin Kure Weeke
- Rigshospitalet - Copenhagen University Hospital, Cardiology , Copenhagen , Denmark
| |
Collapse
|
6
|
Alhakak A, Mogensen UM, Vinther M, Risum N, Jons C, Jacobsen PK, Torp-Pedersen C, Fosbol EL, Kober L, Philbert BT, Weeke PE. Severity of chronic obstructive pulmonary disease and risk of one-year mortality after first-time implantation of implantable cardioverter defibrillator: a nationwide study. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.727] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Current guidelines, on implantable cardioverter defibrillator (ICD), recommend implantation in patients with an expected survival beyond one year. Information on risk of all-cause mortality among ICD recipients with chronic obstructive pulmonary disease (COPD) according to severity of COPD is lacking.
Purpose
We examined the association between the severity of COPD and risk of all-cause mortality within one year after first-time ICD implantation.
Methods
We identified patients ≥18 years old undergoing first-time ICD implantation with COPD using Danish nationwide registries (1 January 2000 to 31 December 2018). All patients were eligible for one-year follow-up. We used concomitant COPD-related pharmacotherapy six months prior to ICD implantation and COPD hospitalisations one year prior to ICD implantation to determine severity of COPD from mild to very severe according to Table 1. Multivariable Cox regression was used to assess risk of one-year all-cause mortality according to severity of COPD. Severity of COPD was adjusted for sex, age, year of implantation, primary prevention, type of ICD, history of atrial fibrillation, stroke, peripheral artery disease, diabetes, cancer, chronic renal disease, and dialysis.
Results
The study population included 1,536 patients with first-time ICD and COPD. The median age was 69.5 years [25th-75th percentile 63.5–74.3 years], and the majority of patients were males (79.4%). Of these, 896 (58.3%) received an ICD for primary prevention, and 485 (31.6%) had cardiac resynchronisation therapy device with defibrillator (CRT-D). In total, 1,348 (87.8%) patients were diagnosed with heart failure. Patients were grouped according to severity of COPD from mild to very severe: Group 1 (N=666), Group 2 (N=72), Group 3 (N=149), Group 4 (N=445), and Group 5 (N=204). Overall, 154/1,536 (10.0%) ICD recipients with COPD died within one year after first-time ICD implantation. No difference in sex and comorbidities was identified according to the five groups of COPD severity. However, ICD recipients with mild intermittent COPD (Group 1) were the youngest (68.3 years [61.8–73.0 years]). According to our multivariable cox regression in Figure 1, patients with very severe COPD (Group 5) were associated with increased risk of all-cause mortality within one year after first-time ICD implantation (adjusted hazard ratio [HR] 1.90 [95% confidence interval [CI]: 1.21–2.98]), compared with mild intermittent COPD (Group 1). The most common causes of death within one year after ICD implantation were attributed to cardiovascular diseases 95/154 (61.7%), respiratory diseases 15/154 (9.7%), and endocrine disorders 12/154 (7.8%).
Conclusion
In this nationwide study, very severe chronic obstructive pulmonary disease was associated with increased risk of all-cause mortality within one year after first-time implantation of implantable cardioverter defibrillator.
Funding Acknowledgement
Type of funding sources: Foundation. Main funding source(s): Independent Research Fund Denmark
Collapse
Affiliation(s)
- A Alhakak
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - U M Mogensen
- Zealand University Hospital, Department of Cardiology , Roskilde , Denmark
| | - M Vinther
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - N Risum
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - C Jons
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - P K Jacobsen
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - C Torp-Pedersen
- Nordsjaellands Hospital, Department of Clinical Research and Cardiology , Hilleroed , Denmark
| | - E L Fosbol
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - L Kober
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - B T Philbert
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| | - P E Weeke
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology , Copenhagen , Denmark
| |
Collapse
|
7
|
Jespersen CHB, Kroell J, Bhardwaj P, Hansen CJ, Svane J, Winkel B, Joens C, Jacobsen PK, Torp-Pedersen C, Koeber L, Tfelt-Hansen J, Weeke PE. Use of non-recommended drugs in Brugada Syndrome: a Danish nationwide cohort study. Europace 2022. [DOI: 10.1093/europace/euac053.015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
To lower the risk of sudden cardiac death, patients with Brugada Syndrome (BrS) are recommended to avoid intake of drugs known to increase the risk of arrhythmias or the development of type-1 BrS ECG. However, information on adherence to these recommendations among patients with BrS is limited.
Purpose
To examine treatment with non-recommended drugs before and after diagnosis with BrS, risk factors of treatment with these drugs, and whether treatment was associated with a higher risk of hospitalization with ventricular arrhythmias or death.
Methods
All patients diagnosed with BrS in Denmark (1995-2018) with >12 months of follow-up were identified through nationwide registries using the ICD-10 diagnosis code DI472M (PPV 95.8%). Relevant BrS risk drugs were identified and grouped as drugs to "avoid" or "preferably avoid" in agreement with the likelihood of promoting arrhythmias and type-1 BrS ECG according to brugadadrugs.org(1) (accessed August 2021). Multiple logistic regression (adjusted for sex, age, year of diagnosis, and relevant comorbidities and drugs) was performed to identify factors associated with risk drug use during follow-up.
Results
We identified 270 patients with BrS. Median age at the time of diagnosis was 46.2 years [IQR 32.6-57.6], 70.4% were male. Before the time of diagnosis, 16 patients (5.9%) were treated with a drug to "avoid" or "preferably avoid" (n=5 and n=12, respectively). During a median follow-up of 79 months, 89 patients (33%) were treated with at least one BrS risk drug after the time of diagnosis (table). A total of 22 patients with BrS (8.1%) received ≥2 different drugs at any time during follow-up. There was no significant difference in proportions of patients receiving a risk drug the year prior to diagnosis (12.2%) compared to each of the five years following diagnosis (year 1-5, respectively: 12.2%; 9.7%; 12.3%; 13.6%; 13.5% (p>0.05 for all)).
Females had an odds ratio (OR) of 2.21 [95% CI 1.21-4.03] for use of risk drugs. Also associated with a greater likelihood of risk drug use after diagnosis were having a psychiatric disease at baseline (OR=4.80 [1.72-13.41]) and any use of a risk drug within 90 days prior to diagnosis (OR=8.54 [2.13-34.31]) (figure).
During follow-up, six patients were hospitalized for ventricular arrhythmias; none had redeemed a prescription of a risk drug. In total, 12 patients died, of which five (41.7%) had redeemed a prescription of one or more risk drugs within 50 days of death.
Conclusions
1/3 patients with BrS received a risk drug at any time point after diagnosis. No change in proportions of patients treated with risk drugs was identified after time of diagnosis. 5/12 patients that died during follow-up had redeemed a prescription of one or more risk drugs within 50 days of death. Female sex, any psychiatric diagnosis, and use of a non-recommended drug before diagnosis with BrS were associated with a greater likelihood of risk drug use after diagnosis.
Collapse
Affiliation(s)
- CHB Jespersen
- Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark
| | - J Kroell
- Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark
| | - P Bhardwaj
- Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark
| | - CJ Hansen
- Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark
| | - J Svane
- Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark
| | - B Winkel
- Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark
| | - C Joens
- Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark
| | - PK Jacobsen
- Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark
| | - C Torp-Pedersen
- Hillerod Hospital, Department of Clinical Investigation and Cardiology, Hillerod, Denmark
| | - L Koeber
- Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark
| | - J Tfelt-Hansen
- Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark
| | - PE Weeke
- Rigshospitalet - Copenhagen University Hospital, Heart Centre, Department of Cardiology, Copenhagen, Denmark
| |
Collapse
|
8
|
Frodi DM, Kolk MZH, Langford J, Andersen TO, Jacobsen PK, Risum N, Tan HL, Knops RE, Svendsen JH, Diederichsen SZ, Tjong FVY. Adherence to wearables in implantable cardioverter-defibrillator patients: Preliminary results from the prospective, multicenter SafeHeart-study. Europace 2022. [DOI: 10.1093/europace/euac053.579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: Public grant(s) – EU funding. Main funding source(s): Horizon2020
Introduction
Wearable devices are gaining interest in the clinical assessment of physical behavior as a marker of disease severity. With the increased use, patient willingness and adherence will be increasingly important. As part of the SafeHeart study, examining the potential of physical behavior as an identifier of clinical deterioration in patients with an implantable cardioverter defibrillator (ICD), we present preliminary results on adherence to a wrist-worn wearable used for physical behavior assessment.
Purpose
Define the willingness to participate and long-term adherence to wearables in an ICD population.
Methods
This is a preliminary analysis of the ongoing multicenter, prospective, observational SafeHeart study. SafeHeart is aimed to construct a personalized prediction engine for ICD therapy using wearable-assessed physical behavior, remote ICD monitoring, electronic health records, and patient-reported data. The study will enroll 400 participants with an ICD with or without cardiac resynchronization therapy (CRT-D). In this preliminary analysis, wearable data was analyzed for the first 50 participants, where inclusion required a minimum of 1 month of follow up data. No data from the wearables were provided to the participants. The wrist-worn wearables were used continuously (day and night) for up to 12 months of follow-up. Adherence to the wearable was measured through patient-reported (subjective) adherence and wearable-measured (objective) adherence. Data were extracted from the wearables and non-wear time was detected via open source algorithms. A valid day was set to 22 hours of available wear time with 24-hour periods assessed from 3pm to 3pm for sleep metric capture. The willingness to participate and dropout rates were calculated for the same first 50 patients of the study.
Results
A total of 50 ICD participants were included in this study. The mean age was 65.1 years, 82 % male, with a mean follow up of 7 weeks, generating 326 patient weeks of data. Regarding patient-reported adherence, participants reported 81.4% full adherence and 18.6 % of participants reported very brief non-wear due to e.g. sauna or surgery. Of those reporting non-wear, 62.5% described one episode only of non-wear lasting 15-75 minutes. Regarding objectively measured adherence from wearable data, full adherence was shown in 91.7% of days. The mean number of valid days per participant was 41.3. Recruitment rates showed a willingness to participate of 50% (50/100) out of eligible subjects invited. No participants were lost to follow
Conclusion
Results show high adherence and reasonable willingness to participate without wearable adherence dropping over time. Comparison of objectively measured and patient-reported adherence showed similar values.
Collapse
Affiliation(s)
- DM Frodi
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - MZH Kolk
- Amsterdam UMC - Location Academic Medical Center, Department of Cardiology, Amsterdam, Netherlands (The)
| | - J Langford
- ActivInsights Ltd., Kimbolton, United Kingdom of Great Britain & Northern Ireland
| | | | - PK Jacobsen
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - N Risum
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - HL Tan
- Amsterdam UMC - Location Academic Medical Center, Department of Cardiology, Amsterdam, Netherlands (The)
| | - RE Knops
- Amsterdam UMC - Location Academic Medical Center, Department of Cardiology, Amsterdam, Netherlands (The)
| | - JH Svendsen
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - SZ Diederichsen
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - FVY Tjong
- Amsterdam UMC - Location Academic Medical Center, Department of Cardiology, Amsterdam, Netherlands (The)
| |
Collapse
|
9
|
Witt C, Jacobsen PK, Johannessen A, Sandgaard NCF, Gang UJO, Hansen PS, Worck R, Riahi S, Nielsen JC, Kristiansen SB. Early mortality and complications following first-time catheter ablation of atrial fibrillation in a nationwide cohort. Europace 2022. [DOI: 10.1093/europace/euac053.150] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Atrial fibrillation (AF) is the most common clinical arrhythmia. Pulmonary vein isolation (PVI) by catheter ablation has become a cornerstone in the treatment of AF. Serious complications to PVI have been reported to be at an acceptable level and risk of death after AF ablation is low.
Purpose
In a contemporary nationwide cohort of patients undergoing first-time PVI by catheter ablation, we wanted to investigate the 30-day mortality after ablation, and to examine risk and potential risk factors of PVI-related complications.
Methods
Population-based cohort study in patients who underwent first-time PVI by catheter ablation between 2011-2018 identified from the National Danish Ablation Registry. Primary outcome was early post-procedural mortality, defined as death of any cause within 30 days of index PVI procedure, or in connection to a hospitalization started within 30 days. Secondary outcomes were all-cause rehospitalization and complication, including postoperative infection, cardiac, vascular, neurological, vascular, and pulmonary complications within 30 days. Data on mortality and complications were collected from national health and administrative registries. Binary regression was used to estimate risk ratio (RR) with 95% confidence intervals (CI) for association between selected predictors and any complication, and adjusted gender, age, BMI, prior ablation, calendar period (ablation from 2011-2013, 2014-2016, and >2016).
Results
We included 8560 patients. Median age was 62, 66% were men, 12% had a history of heart failure, and median CHA2DS2VASc score was 1 (Interquartile range [IQR]; 1-2). Charlton Comorbidity index (CCI) was none in 66%, moderate in 29% and severe in 5%. A total of 10 (0.12%) patients died within 30 days of ablation, of which 4 patients died during initial hospitalization. Median time to death was 20 (IQR, 12 to 29) days. Patients who died were more likely to have experienced a procedure-related complication (40% vs. 4%, P<0.001). Procedure-related complications occurred in 298 (3.5%), and the risk was 4.4%, 3.0% and 3.3% in the time periods between 2011-2013, 2014-2016 and >2016, respectively. Most common complications were postoperative infection (26%), cardiac complication (26%), and vascular complications (18%). Complication risk was increased in patients with higher age (aRR, 65-74 year; 1.67 [1.32-2.11] and >74 years; 2.48 [1.60-3.84]), moderate CCI (aRR 1.45 [1.14-1.83]), cardiovascular disease (aRR 1.52 [1.09-2.11]) and antithrombotic treatment (aRR 1.41 [1.05-1.89]). After first-time PVI, 1.963 (23%) patients were re-hospitalized within 30 days, and most common primary discharge diagnoses were AF (87%) and direct cardioversion was performed in 765 (39%) patients.
Conclusion
In a nationwide cohort of patients who underwent first-time PVI, number of deaths within 30 days of ablation was low (0.12%). Risk of complication was low and 23% of the patients were re-hospitalized within 30 days.
Collapse
Affiliation(s)
- C Witt
- Aarhus University Hospital, Aarhus, Denmark
| | - PK Jacobsen
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - A Johannessen
- Glostrup Hospital - Copenhagen University Hospital, Copenhagen, Denmark
| | | | - UJO Gang
- Zealand University Hospital, Roskilde, Denmark
| | | | - R Worck
- Glostrup Hospital - Copenhagen University Hospital, Copenhagen, Denmark
| | - S Riahi
- Aalborg University Hospital, Aalborg, Denmark
| | - JC Nielsen
- Aarhus University Hospital, Aarhus, Denmark
| | | |
Collapse
|
10
|
Thomsen AF, Bertelsen L, Jons C, Jabbari R, Lonborg JT, Ekstrom K, Tilsted HH, Pedersen F, Kober L, Engstrom T, Vejlstrup N, Jacobsen PK. Scar related border zone channels assessed with cardiac MRI are associated with ventricular arrhythmia in patients with ST-segment elevation myocardial infarction. Europace 2022. [DOI: 10.1093/europace/euac053.343] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Introduction
Prediction of scar-related ventricular arrhythmia in ST-Segment Elevation Myocardial Infarction (STEMI) is important, but currently difficult. Late gadolinium enhancement cardiac magnetic resonance (LGE-CMR) permits characterization of left ventricular (LV) ischemic scars, including differentiation between core, border zone (BZ) and BZ channels. The latter represents potential electrical circuits of slow conductivity responsible for ventricular arrhythmic events. We hypothesized that detailed BZ channel characterization potentially serves as a risk marker for ventricular arrhythmia, therefore contributing to risk stratification following STEMI.
Purpose
The aim of this study was to assess scar-related arrhythmic BZ channels with advanced CMR in STEMI patients developing subsequent ventricular arrhythmia compared with controls.
Methods
This is a CMR sub-study of the DANAMI-3 STEMI multicenter trial (year 2011, n=1234) and Danegaptide phase II proof-of-concept clinical trial (year 2013, n=591). All patients were admitted for primary PCI in all primary PCI centers in Denmark. A total of 779 patients had a 3-month follow-up CMR. Of these, 21 patients subsequently experienced ventricular arrhythmia during 68 months of follow-up and were randomly matched 1:2 with 42 controls, who constituted the study population. Matching were based on left ventricular ejection fraction (LVEF), infarct location, culprit vessel, and revascularization status in patients with multivessel disease. Ischemic scar tissue including core, BZ and BZ channels were automatically detected by a specialized investigational software (1). To differentiate BZ from healthy tissue and BZ from core, thresholds of 40% ± 5% and 60% ± 5% of the maximum signal intensity were applied. A BZ channel in the LGE-CMR reconstruction was defined as a continuous corridor of BZ between 2 core areas or between a core area and a valve annulus (Figure 1).
Results
We included 63 patients (median age: 58.0 years; 84% men; median LVEF: 45 ± 10%), of whom 30 (48%) patients had an anterior located infarction, and 45 (71%) patients were completely revascularized. The median time from STEMI to a ventricular arrhythmic event was 3 ± 2 years. A significantly higher number of patients with ventricular arrhythmia had BZ channels (n=16 (76%) vs. n=18 (43%), P=0.02) including an increased number of BZ channels (2 ± 2 vs. 1 ± 1, P=0.02) compared with controls. Patients with subsequent ventricular arrhythmia had a larger scar mass (core mass + BZ mass) (27 ± 17g vs. 19 ± 11g; P=0.03), core mass (9 ± 8g vs. 6 ± 5g; P=0.06) and BZ mass (18 ± 10g vs. 13 ± 7g; P=0.01).
Conclusion(s)
Border zone channels visualized by LGE-CMR were associated with subsequent development of ventricular arrhythmia in patients with STEMI and may serve as risk stratification following STEMI.
Collapse
Affiliation(s)
- AF Thomsen
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - L Bertelsen
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - C Jons
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - R Jabbari
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - JT Lonborg
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - K Ekstrom
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - HH Tilsted
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - F Pedersen
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - L Kober
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - T Engstrom
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - N Vejlstrup
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| | - PK Jacobsen
- Rigshospitalet - Copenhagen University Hospital, Copenhagen, Denmark
| |
Collapse
|
11
|
Thomsen A, Pedersen S, Jacobsen PK, Huikuri HV, Bloch Thomsen PE, Jons C. P1868Risk of arrhythmias after myocardial infarction in patients with left ventricular systolic dysfunction according to mode of revascularization: a CARISMA substudy. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0618] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
The CARISMA trial was the first study to use continuous monitoring for documentation of long-term arrhythmias in post-infarction patients with left ventricular dysfunction. During the study duration (2000–2005), primary PCI (pPCI) as treatment of acute myocardial infarction was introduced approximately midway (2002) on the enrolling centres.
Purpose
The aim of this study was to describe the influence of mode of revascularization after myocardial infarction (AMI) on long-term risk of risk of new onset atrial fibrillation, ventricular tachyarrhythmias and brady arrhythmias.
Methods
The study is a sub-study on the CARISMA study population that consisted of patients with AMI and left ventricular ejection fraction ≤40%, which received an implantable loop recorder and was followed for 2 years. After exclusion of 15 patients who refused device implantation and 26 with pre-existing arrhythmias, 268 of the 312 patients were included. Choice of revascularization was made by the treating team independently of the trial and was retrospectively divided into primary percutaneous intervention (pPCI), subacute PCI (24 hours to 2 weeks after AMI), primary thrombolysis or no revascularization.
Endpoints were new-onset of arrhythmias and major cardiovascular events (MACE). The Kaplan-Meier (figure 1) and Mantel-Byar methods were used for time to first event risk analysis.
Results
A total of 77 patients received no revascularization, whereas 49 received thrombolysis only and 142 received PCI. At two-years follow up patients treated with any PCI had a significant lower risk (0.40, n=63) of any arrhythmia compared to patients treated with trombolysis (0.60, n=30) or no revascularization (0.68, n=16) (p<0.001, unadjusted) (figure 1). Risk of MACE was significant higher in patients with any arrhythmia (0.25, n=76) compared to no arrhythmia (0.11, n=93) at two years follow-up (p=0.004, unadjusted).
Figure 1
Conclusion(s)
The long-term risk of new onset arrhythmias after AMI was significantly lower in patients treated with any PCI compared to patients not revascularized or treated with thrombolysis. Risk of MACE was significantly higher in patients with new onset arrhythmias compared to patients with no arrhythmias.
Collapse
Affiliation(s)
- A Thomsen
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, Copenhagen, Denmark
| | - S Pedersen
- Gentofte University Hospital, Department of Cardiology, Copenhagen, Denmark
| | - P K Jacobsen
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, Copenhagen, Denmark
| | - H V Huikuri
- Oulu University Hospital, Department of Cardiology, Oulu, Finland
| | | | - C Jons
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, Copenhagen, Denmark
| |
Collapse
|
12
|
Giehm-Reese M, Kronborg MB, Lukac P, Kristiansen SB, Nielsen JM, Johannessen A, Jacobsen PK, Djurhuus MS, Riahi S, Hansen PS, Nielsen JC. P2845Recurrent atrial flutter and incidence of atrial fibrillation ablation after first-time ablation for typical atrial flutter: a nation-wide Danish cohort study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.1155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Cavo tricuspid isthmus ablation (CTIA) is an effective first-line treatment for typical atrial flutter (AFL). However, many patients develop atrial fibrillation (AF) after successful CTIA. Knowledge about recurrent arrhythmia after CTIA mainly comes from small cohort studies with limited follow-up.
Purpose
To describe incidences of AFL re-ablation and AF-ablation after first-time CTIA in a nation-wide cohort.
Method
In the Danish National Ablation Registry we identified patients undergoing first-time CTIA during 2010–2016. Subsequent CTIA and AF-ablation procedures were identified until March 1st, 2018. We gathered information on patient comorbidities in the Danish National Patient Registry.
Results
We identified 2409 patients undergoing first-time CTIA. Median age was 66 (IQR 58–72) years, and 1952 (81%) were men. 78 (3%) had a history of AF. Acute procedural succes was achieved in 2288 (95%) patients. During mean follow-up of 4±1.7 years, 242 (10%) patients underwent CTI re-ablation and 326 (13.5%) ablation for AF. Baseline characteristics associated with CTI re-ablation included prolonged procedural time, unsuccessful first CTIA, age<75 years and CHA2DS2-VASc score<2. Hypertension, history of AF, age<65 years and CHA2DS2-VASc score<2 were associated with later AF-ablation (Table).
Predictive characteristics Characteristics associated with CTI re-ablation HR 95% CI p-value Procedural time 1.003 (1.001–1.006) 0.01 Unsuccesful first CTIA procedure 3.42 (2.10–5.55) <0.0001 Age <75 years 1.52 (1.03–2.26) 0.04 CHA2DS-VAS2c score <2 1.45 (1.11–1.90) 0.01 Characteristics associated with later AF-ablation Hypertension 1.31 (1.02–1.69) 0.04 History of AF 1.70 (1.07–2.71) 0.03 Age <65 years 2.38 (1.89–3.01) <0.0001 CHA2DS-VAS2c score <2 1.77 (1.40–2.45) <0.0001 AF: Atrial fibrillation; HR: Hazard ratio. All HR's are adjusted for age, gender, hypertension, diabetes, heart failure, iscemic heart disease, valvular heart disease, chronic obstructive lung disease, chronic kidney disease and history of AF using Cox regression analysis.
Conclusion
In a nation-wide cohort undergoing CTIA for AFL, 10% of patients underwent CTI re-ablation and 13.5% were ablated for AF during mean follow-up of 4±1.7 years. Probability of undergoing a second ablation procedure was higher in younger patients with less comorbidity.
Collapse
Affiliation(s)
- M Giehm-Reese
- Skejby University Hospital, Department of Cardiology, Aarhus, Denmark
| | - M B Kronborg
- Skejby University Hospital, Department of Cardiology, Aarhus, Denmark
| | - P Lukac
- Skejby University Hospital, Department of Cardiology, Aarhus, Denmark
| | - S B Kristiansen
- Skejby University Hospital, Department of Cardiology, Aarhus, Denmark
| | - J M Nielsen
- Skejby University Hospital, Department of Cardiology, Aarhus, Denmark
| | - A Johannessen
- Gentofte University Hospital, Department of Cardiology, Copenhagen, Denmark
| | - P K Jacobsen
- Rigshospitalet - Copenhagen University Hospital, Department of Cardiology, Copenhagen, Denmark
| | - M S Djurhuus
- Odense University Hospital, Department of Cardiology-B, Odense, Denmark
| | - S Riahi
- Aalborg University Hospital, Department of Cardiology, Aalborg, Denmark
| | - P S Hansen
- Mølholm Private Hospital, Department of Cardiology, Vejle, Denmark
| | - J C Nielsen
- Skejby University Hospital, Department of Cardiology, Aarhus, Denmark
| |
Collapse
|
13
|
Pallisgaard JL, Schjerning AM, Hansen ML, Johannessen A, Gustafsson F, Gislason GH, Torp-Pedersen C, Jacobsen PK, Kristensen SL, Koeber L, Schou M. 3377Ablation for atrial fibrillation with heart failure should be performed early a nationwide study. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy563.3377] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
| | - A.-M Schjerning
- Herlev Hospital - Copenhagen University Hospital, Cardiology, Copenhagen, Denmark
| | - M L Hansen
- Gentofte University Hospital, Cardiology, Copenhagen, Denmark
| | - A Johannessen
- Gentofte University Hospital, Cardiology, Copenhagen, Denmark
| | - F Gustafsson
- Rigshospitalet - Copenhagen University Hospital, Cardiology, Copenhagen, Denmark
| | - G H Gislason
- Gentofte University Hospital, Cardiology, Copenhagen, Denmark
| | - C Torp-Pedersen
- Aalborg University Hospital, Cardiology and Epidemiology, Aalborg, Denmark
| | - P K Jacobsen
- Rigshospitalet - Copenhagen University Hospital, Cardiology, Copenhagen, Denmark
| | | | - L Koeber
- Rigshospitalet - Copenhagen University Hospital, Cardiology, Copenhagen, Denmark
| | - M Schou
- Herlev Hospital - Copenhagen University Hospital, Cardiology, Copenhagen, Denmark
| |
Collapse
|
14
|
Dang S, Jacobsen PK, Pehrson S, Chen X. P461Catheter ablation of idiopathic ventricular fibrillation using remote magnetic navigation. Europace 2018. [DOI: 10.1093/europace/euy015.270] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- S Dang
- Wuxi people's hospital Affiliated to Nanjing Medical University, Department of cardiology, Wuxi, China People's Republic of
| | | | | | - X Chen
- Rigshospitalet, copenhagen, Denmark
| |
Collapse
|
15
|
Reinhard H, Jacobsen PK, Lajer M, Pedersen N, Billestrup N, Mandrup-Poulsen T, Parving HH, Rossing P. Multifactorial treatment increases endothelial progenitor cells in patients with type 2 diabetes. Diabetologia 2010; 53:2129-33. [PMID: 20607514 DOI: 10.1007/s00125-010-1843-4] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/18/2010] [Accepted: 06/11/2010] [Indexed: 10/19/2022]
Abstract
AIMS/HYPOTHESIS Endothelial progenitor cells (EPC) augment vascular repair and neovascularisation. Patients with type 2 diabetes have reduced EPC and increased risk of cardiovascular disease (CVD), which is reduced by multifactorial intervention. Our aim, therefore, was to evaluate in type 2 diabetic patients whether the numbers of EPC derived from peripheral blood mononuclear cells is influenced by a multifactorial treatment strategy. METHODS We enrolled 28 patients newly referred for initiation of multifactorial treatment, which consisted of improving glycaemic, lipid and blood pressure control, as well as antithrombotic therapy and lifestyle modification. EPC count was assessed by in vitro cultures at baseline and after 90 days of treatment. After 7 days in culture, we identified EPC by fluorescent staining of attached cells. Patients were treated with metformin, aspirin, statins and angiotensin II receptor blockers, and divided accordingly into groups of mono-, dual-, triple- or quadruple therapy. RESULTS After 90 days of treatment, glycaemic control improved and total cholesterol decreased. Multifactorial intervention for 90 days significantly increased EPC count in cultures by 35% (from 105 [SE 8] to 140 [11] cells per field [p = 0.002]). The change in EPC among patients with quadruple therapy was higher (63%) than in untreated patients (-32%, p = 0.043). CONCLUSIONS/INTERPRETATION Numbers of EPC derived from peripheral blood mononuclear cells increased significantly after multifactorial intervention in type 2 diabetic patients. It remains to be shown whether these changes contribute to the beneficial effects of multifactorial intervention on diabetic micro- and macroangiopathy.
Collapse
Affiliation(s)
- H Reinhard
- Steno Diabetes Center, Niels Steensenvej 1, DK-2820 Gentofte, Denmark.
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Lund SS, Tarnow L, Astrup AS, Hovind P, Jacobsen PK, Alibegovic AC, Parving I, Pietraszek L, Frandsen M, Rossing P, Parving HH, Vaag AA. Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes. Diabetes Obes Metab 2009; 11:966-77. [PMID: 19558610 DOI: 10.1111/j.1463-1326.2009.01079.x] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
BACKGROUND In addition to its glucose-lowering effect, metformin treatment has been suggested to improve lipidaemia in patients with type 2 diabetes. In contrast, in patients with type 1 diabetes (T1DM), information about the effect of metformin treatment on lipidaemia is limited. In this study, we report the effect of a 1-year treatment with metformin vs. placebo on plasma lipids in T1DM patients and persistent poor glycaemic control. METHODS One hundred T1DM patients with haemoglobinA(1c) (HbA(1c)) > or =8.5% during the year before enrolment entered a 1-month run-in period on placebo treatment. Thereafter, patients were randomized (baseline) to treatment with either metformin (1000 mg twice daily) or placebo for 12 months (double masked). Patients continued ongoing insulin therapy and their usual outpatient clinical care. Outcomes were assessed at baseline and after 1 year. RESULTS After 1 year, in those patients who did not start or stop statin therapy during the trial, metformin treatment significantly reduced total and LDL cholesterol by approximately 0.3 mmol/l compared with placebo (p = 0.021 and p = 0.018 respectively). Adjustment for statin use or known cardiovascular disease did not change conclusions. In statin users (metformin: n = 22, placebo: n = 13), metformin significantly lowered levels of LDL and non-HDL cholesterol by approximately 0.5 mmol/l compared with placebo (adjusted for changes in statin dose or agent: p = 0.048 and p = 0.033 respectively). HbA(1c) (previously reported) was not significant different between treatments. CONCLUSION In patients with poorly controlled T1DM, at similar glycaemic levels, adjunct metformin therapy during 1 year significantly lowered levels of proatherogenic cholesterolaemia independent of statin therapy.
Collapse
Affiliation(s)
- S S Lund
- Steno Diabetes Center, Niels Steensens Vej 2, 2820 Gentofte, Denmark.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Jacobsen PK, Tarnow L, Parving HH. Time to consider ACE insertion/deletion genotypes and individual renoprotective treatment in diabetic nephropathy? Kidney Int 2006; 69:1293-5. [PMID: 16612410 DOI: 10.1038/sj.ki.5000283] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
One reason for the inadequacy of current renoprotective therapy and the persistent poor renal prognosis in diabetic nephropathy is the large interindividual variation in response to treatment. Genetic as well as non-genetic factors are known to influence treatment efficacy. This Commentary summarizes the impact of the angiotensin-converting enzyme (ACE) insertion/deletion polymorphism in the ACE gene on initiation and progression of diabetic nephropathy.
Collapse
|
18
|
Jensen GH, Jacobsen PK, Korsgaard F. [Pseudomonas aeruginosa as the cause of meningitis in a patient with epidural catheter]. Ugeskr Laeger 2000; 162:2893-4. [PMID: 10860430] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/14/2023]
Abstract
A case of epidural infection following epidural catheterization is presented. The clinical signs initially were backpain and a small swelling at the site of insertion. Treatment with dicloxacillin was begun, presuming a Staphylococcus-infection. The symptoms persisted. Weeks later the patient developed meningitis and Pseudomonas aeruginosa was cultivated. Antibiotic treatment was changed to ceftazidime, netilmycin and ciprofloxacin. Complete recovery followed.
Collapse
Affiliation(s)
- G H Jensen
- Vejle Sygehus, anaestesiologisk afdeling
| | | | | |
Collapse
|